Executive Overview: The Global Upadacitinib Market The global Upadacitinib market is experiencing exceptional growth, driven by increasing demand for effective JAK1 inhibitors in autoimmune and inflammatory disease treatment. Upadacitinib (brand name RINVOQ), developed by AbbVie, serves as a selective JAK1 inhibitor​ with applications spanning rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and giant cell arteritis . The market demonstrates remarkable expansion, with Upadacitinib achieving global sales of $5.971 billion in 2024, representing year-over-year growth of 50.44%​ . The drug’s success is further evidenced by its recent expansion into new indications, with AbbVie submitting applications to the FDA and EMA in February 2026 for treatment of…